Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease at the 19th International Celiac Disease Symposium
Positive Phase 1 Data Support Near-term Initiation of Global Phase 2 Trial
Excerpt from the Press Release:
CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that data from the Phase 1 ACeD (Assessment of KAN-101 in Celiac Disease) clinical trial evaluating its lead candidate, KAN-101, for the treatment of individuals with celiac disease will be presented during an encore poster presentation on October 21, 2022, at 2:00 p.m. CET at the 19th International Celiac Disease Symposium (ICDS). The Symposium is being held October 19-21, 2022, in Sorrento, Italy.
Celiac disease is a serious autoimmune disease triggered by ingestion of gluten for which there are no approved therapeutic treatments available. KAN-101 is designed to induce tolerance to gliadin, a core component of gluten, through natural pathways in the liver. Findings from the ACeD trial showed that treatment with KAN-101 was safe and tolerated in patients treated, and reduced T cell responses following a gluten challenge. Based on the results from the Phase 1 trial, Anokion is preparing to initiate a global Phase 2 trial of KAN-101 in patients with celiac disease.
“The data observed in our Phase 1 trial with KAN-101 are highly encouraging, demonstrating clear reduction of T cell responses, and a dose-dependent inhibition of gluten-induced serum IL-2 (interleukin-2), a key disease biomarker that may correlate with the timing and severity of symptoms after gluten exposure in celiac disease,” said Deborah Geraghty, Ph.D., chief executive officer of Anokion. “These data suggest that our KAN-101 product candidate could be the first disease-modifying approach to treating celiac disease. Based on these findings, we are working closely with our global sites to prepare for patient enrollment in a global Phase 2 clinical trial by the end of the year, taking us a critical step forward to bringing a potential life-changing treatment to individuals with celiac disease.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?